375 related articles for article (PubMed ID: 29256330)
1. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
[TBL] [Abstract][Full Text] [Related]
4. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
5. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
Omuro A; Taillandier L; Chinot O; Sierra Del Rio M; Carnin C; Barrie M; Soussain C; Tanguy ML; Choquet S; Leblond V; Hoang-Xuan K;
J Neurooncol; 2011 Aug; 104(1):323-30. PubMed ID: 21170569
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
8. Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.
Koh HK; Kim IH; Kim TM; Lim DH; Oh D; Cho JH; Kim WC; Kim JH; Chung WK; Jeong BK; Kang KM; Hong S; Suh CO; Kim IA
J Neurooncol; 2017 Dec; 135(3):629-638. PubMed ID: 28939931
[TBL] [Abstract][Full Text] [Related]
9. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
[TBL] [Abstract][Full Text] [Related]
10. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Suzuki Y; Imoto N; Ishihara S; Fujiwara S; Ito R; Sakai T; Yamamoto S; Sugiura I; Kurahashi S
Intern Med; 2022 May; 61(9):1345-1352. PubMed ID: 34670884
[TBL] [Abstract][Full Text] [Related]
12. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
[TBL] [Abstract][Full Text] [Related]
15. Significance of treatment response when managing patients with primary central nervous system lymphoma.
Chan H; Moraes FY; Berlin A; Crump M; Mason W; Laperriere N; Kuruvilla J; Prica A
Leuk Lymphoma; 2019 Feb; 60(2):349-357. PubMed ID: 29966463
[TBL] [Abstract][Full Text] [Related]
16. Current management of primary central nervous system lymphoma.
Schultz CJ; Bovi J
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):666-78. PubMed ID: 20159361
[TBL] [Abstract][Full Text] [Related]
17. [A single-center, retrospective analysis of relapse and progression patterns of primary central nervous system lymphoma: can whole brain radiotherapy be replaced?].
Qin Y; Liu R; Zhang X; Zhang W; Ren C; Wu D
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Apr; 43(4):499-506. PubMed ID: 37202184
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
20. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
